I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in envelope with sufficient postage affixed and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, . 22313-1450 on January 12, 2004.

Esther Lily C. Esguerra

Signature

Attorney Docket No.: 10201-20003.10

(formerly CYTOP002D1)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication

Kathleen A. ELIAS

Confirmation No.:

9501

of:

Serial No.: 10/082,036 Art Unit:

1631

Filed:

February 20, 2002

Examiner:

J. Brusca

For:

METHOD OF CHARACTERIZING POTENTIAL THERAPEUTICS BY **DETERMINING CELL-CELL**

INTERACTIONS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

To assist the Examiner, the documents are listed on the attached PTO-Form 1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Document nos. A01 through B39 and C01 through C20 are listed in the accompanying PTO form 1449, and were previously submitted in prior application serial no. 09/741,721 filed December 18, 2000, now U.S. Patent No. 6,599,694, issued July 29, 2003, thus no copies of these references are being provided. However, pursuant to 37 C.F.R. §1.98, copies of document nos. B40 (WO 00/73414), and B41 (WO 00/65472) are being provided for the examiner's review.

By citing the references in the accompanying PTO form 1449, Applicants do not acquiesce or admit that any of these documents are "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37. C.F.R. §1.131, §1.604, 1.608 or any other suitable means.

01/28/2004 SLUANG1 00000011 501339

180.00 DA

01 FC:1806

This Information Disclosure Statement is being submitted after the mailing of a first Office Action on the merits, or after three months of the filing date of this application, whichever event occurred last, but it is believed before the mailing date of either: (i) a final action under § 1.113 or (ii) a notice of allowance under §1.311, whichever occurs first. Please charge \$180.00 to our Deposit Account 50-1339. If it is determined that any fees are due, the Commissioner is hereby authorized to charge the requisite fees to Deposit Account No. 50-1339.

Respectfully submitted.

Date: January 12, 2004

48,070

(Reg. No.)

Julie H. Heinrich, Ph.D.
SWISS LAW GROUP
Ruilding 3, Pale Alto Say

Building 3, Palo Alto Square 3000 El Camino Real, Suite 100

Palo Alto, CA 94306 T (650) 856-3700 F (650) 856-3710

ATTY DOCKET NO. APPLICATION NO 10201-20003.10 10/082,036 Use several sheets if necessary) APPLICANT JAN 1 6 2004 & Kathleen A. ELIAS GROUP FILING DATE RADFILM 1631 February 20, 2002

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,818,710	4/1989	Sutherland et al.			
	A02	4,922,092	5/1990	Rushbrooke et al.			
	A03	4,959,301	9/1990	Weaver et al.			
	A04	4,965,725	10/1990	Rutenberg			
-	A05	RE 34,214	4/1993	Carlsson et al.			
	A06	5,287,272	2/1994	Rutenberg et al.			
	A07	5,326,691	10/1999	Hozier			
	A08	5,355,215	10/1994	Schroeder et al.			
	A09	5,526,258	6/1996	Bacus			
	A10	5,548,661	8/1996	Price et al.			
	A11	5,655,028	8/1997	Soll	-		
	A12	5,733,721	3/1998	Hemstreet, III et al.			
	A13	5,741,648	4/1998	Hemstreet III et al.			
	A14	5,776,748	7/1998	Singhvi et al.			
	A15	5,790,692	8/1998	Price et al.			
	A16	5,790,710	8/1998	Price et al.			
	A17	5,804,436	9/1998	Okun et al.			
	A18	5,856,665	1/1999	Price et al.			
	A19	5,893,095	4/1999	Jain et al.			
	A20	5,919,646	7/1999	Okun et al.			
	A21	5,932,872	8/1999	Price			
	A22	5,962,250	10/1990	Gavin et al.			
	A23	5,962,520	10/1999	Smith et al.			
	A24	5,976,825	11/1999	Hochman			
	A25	5,976,826	11/1999	Singhvi et al.			
·	A26	5,989,835	11/1999	Dunlay et al.			
	A27	5,991,028	11/1999	Cabib et al.			
	A28	5,995,143	11/1999	Price et al.			
	A29	6,007,996	12/1999	McNamara			
	A30	6,008,010	12/1999	Greenberger et al.			
	A31	6,083,763	7/2000	Balch			
	A32	6,103,479	8/2000	Taylor			
	A33	6,146,830	11/2000	Friend et al.			
	A34	6,222,093	4/2001	Marton et al.			
	A35	6,345,115	2/2002	Ramm et al.			

	6 200		FOREIGN PATENT DOCUMENTS					
<u> </u>		OCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	ION
ENT IT	ADEMA	0317139	5/1989	Europe			YES	N
		0468705	7/1991	Europe				-
	B02	0902394	3/1999	Europe		-		H
	B03	WO 87/02802	5/1987	WIPO				┝
	B04	WO 93/21511	10/1993	WIPO		_		-
	B05	WO 94/11841	5/1994	WIPO		<u> </u>		L
	B06	WO 95/10036						<u> </u>
	B07		4/1995	WIPO				ļ
	B08	WO 95/22749	8/1995	WIPO				<u> </u>
	B09	WO 96/01438	1/1996	WIPO				L
	B10	WO 96/09605	3/1996	WIPO				<u> </u>
	B11	WO 97/20198	6/1997	WIPO				
	B12	WO 97/40055	10/1997	WIPO				_
	B13	WO 97/43732	11/1997	WIPO				_
	B14	WO 97/45730	12/1997	WIPO				<u> </u>
	B15	WO 98/05959	2/1998	WIPO				
	B16	WO 98/35256	8/1998	WIPO				
	B17	WO 98/38490	9/1998	WIPO				
	B18	WO 98/44333	10/1998	WIPO				
	B19	WO 98/45704	10/1998	WIPO				
-	B20	WO 99/08091	2/1999	WIPO				
	B21	WO 99/17116	5/1999	WIPO				
	B22	WO 99/39184	8/1999	WIPO				
	B23	WO 99/44062	9/1999	WIPO				
	B24	WO 99/54494	10/1999	WIPO				
	B25	WO 99/67739	12/1999	WIPO				
	B26	WO 00/03246	1/2000	WIPO				
	B27	WO 00/06774	2/2000	WIPO				
	B28	WO 00/17624	3/2000	WIPO				
	B29	WO 00/17643	3/2000	WIPO				
	B30	WO 00/17808	3/2000	WIPO		 		-
	B31	WO 00/26408	5/2000	WIPO	-			-
	B32	WO 00/29984	5/2000	WIPO				\vdash
	B33	WO 00/31534	6/2000	WIPO				\vdash
	B34	WO 00/33250	6/2000	WIPO				-
	B35	WO 00/43820	7/2000	WIPO				\vdash
	B36	WO 00/49540	8/2000	WIPO				+
	B37	WO 00/50872	8/2000	WIPO				\vdash
	B37	WO 00/60356	10/2000	WIPO	-			\vdash
	B39	WO 00/70528	11/2000	WIPO				-
	ļ	WO 00/73417 J	12/2000	WIPO	_			-
	B40	WO 00/65472 /	11/2/2000	WIPO				<u>L</u>

N 7 0 2004		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
TRADEMARTH	C01	Blankenstein, et al., "Modular Concept of a Laboratory on a Chip for Chemical and Biochemical Analysis," Biosensors & Bioelectronics, Vol. 13, Nos. 3-4, pp. 427-438 (1998).
	C02	Cseke, I., et al., "A Fast Segmentation Scheme for White Blood Cell Images," IEEE, pp. 530-533 (1992).
	C03	Giuliano, K.A., et al., "High-Content Screening: A New Approach to Easing Key Bottlenecks in the Drug Discovery Process," J. Biomolecular Screening, Vol. 2, No. 4, page 249 (1997).
	C04	Giuliano, K.A., et al., "Fluorescent-Protein Biosensors: New Tools for Drug Discovery," Trends in Biotechnology, Vol. 16, No. 3, pp. 135-140 (March 1998).
	C05	Hofland, et al., "Role of Tumor-Derived Fibroblasts in the Growth of Primary Cultures of Human Breast-Cancer Cells: Effects of Epidermal Growth Factor and the Somatostatin Analogue Octreotide," Int. J Cancer, Vol. 60, pp. 93-99 (1995).
	C06	Montironi, R., et al., "Computed Cell Cycle and DNA Histogram Analyses in Image Cytometry in Breast Cancer," J Clin. Path., Vol. 46, No. 9, pp. 795-800 (September 1993).
	C07	Pauwels, et al., "Monitoring of Chemotherapy-Induced Morphonuclear Modifications by Means of Digital Cell-Image Analysis," J. Cancer Res. Clin. Oncol., Vol. 119, pp. 533-540 (1993).
	C08	Pauwels, et al., "Combination of Computerized Morphonuclear and Multivariate Analyses to Characterize In Vitro the Antineoplastic Effect of Alkylating Agents," J. Pharmacol. And Toxicol. Meth., Vol. 33, No. 1, pp. 34-45 (1995).
	C09	Pauwels, et al., "Determination of the Mechanism of Action of Anticancer Drugs by Means of the Computer-Assisted Microscope Image Analysis of Feulgen-Stained Nuclei," J. Pharm. And Toxicological Meth., Vol. 37, pp. 105-115 (1997).
-	C10	Pauwels, et al., "In Vitro Digital Cell Image Analysis of Morphonuclear Modifications Induced by Natural DNA-Interacting Anticancer Drugs in Three Neoplastic Cell Lines," Meth. Find. Exp. Clin. Pharmacol., Vol. 17, No. 3, pp. 151-161 (1995).
	C11	Pauwels, et al., "The Application of Computerized Analysis of Nuclear Images and Multivariate Analysis to the Understanding of the Effects of Antineoplastic Agents and Their Mechanism of Action," Meth. Find. Exp. Clin. Pharmacol., Vol. 15, No. 2, pp. 113-124 (1993).
	C12	Printout from Q3DM Website (www.Q3DM.com), printed on March 1, 2001, 30 pages.
	C13	Printout from Automated Cell Website (www.automatedcell.com) printed on March 9, 2001, 24 pages.
	C14	Rubas, et al., "An Integrated Method to Determine Epithelial Transport and Bioactivity of Oral Drug Candidates in Vitro," Pharmaceutical Research, Vol. 13, No. 1, pp. 23-27 (1996).
	C15	Rubas, et al., "An Integrated Method to Determine Epithelial Transport and Bioactivity of Oral Drug Candidates in Vitro," Pharmaceutical Research, Vol. 13, No. 1, pp. 23-27 (1996).
	C16	Serbouti, S., et al., "Image Segmentation and Classification Methods to Detect Leukemias," Annual Int'l Conf. of IEEE Eng. In Medicine & Biology Soc., Vol. 13, No. 1, pp. 0260-0261 (1991).
	C17	Stearns M.E., et al., "Interleukin 10 (IL-10) Inhibition of Primary Human Prostate Cell-Induced Angiogenesis: IL-10 Stimulation of Tissue Inhibitor of Metalloproteinase-1 and Inhibition of Matrix Metalloproteinase (MMP)-2/MMP-9 Secretion," Clinical Cancer Research, Vol. 5, No. 1, pp. 189-96 (January 1999).
	C18	Takayama, et al., "Patterning Cells and Their Environments Using Multiple Laminar Fluid Flows in Capillary Networks," Cell Biology, Applied Physical Sciences, Proc. Natl. Acad. Sci., Vol. 96, pp. 5545-5548 (May 1999).
	C19	Uria, J.A., et al., "Regulation of Collagenase-3 Expression in Human Breast Carcinomas in Mediated by Stromal-Epithelial Cell Interactions," Cancer Res., Vol. 57, No. 21, pp. 4882-4884 (November 1, 1997).
	C20	Weinstein, et al., "An Information-Intensive Approach to the Molecular Pharmacology of Cancer," Science, Vol. 275, pp. 43-349 (January 17, 1997).
	C21	

EXAMINER		DATE CONSIDERED
	•	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.